Rodent models of treatment-resistant depression
- PMID: 25460020
- PMCID: PMC4423538
- DOI: 10.1016/j.ejphar.2014.10.063
Rodent models of treatment-resistant depression
Abstract
Major depression is a prevalent and debilitating disorder and a substantial proportion of patients fail to reach remission following standard antidepressant pharmacological treatment. Limited efficacy with currently available antidepressant drugs highlights the need to develop more effective medications for treatment- resistant patients and emphasizes the importance of developing better preclinical models that focus on treatment- resistant populations. This review discusses methods to adapt and refine rodent behavioral models that are predictive of antidepressant efficacy to identify populations that show reduced responsiveness or are resistant to traditional antidepressants. Methods include separating antidepressant responders from non-responders, administering treatments that render animals resistant to traditional pharmacological treatments, and identifying genetic models that show antidepressant resistance. This review also examines pharmacological and non-pharmacological treatments regimes that have been effective in refractory patients and how some of these approaches have been used to validate animal models of treatment-resistant depression. The goals in developing rodent models of treatment-resistant depression are to understand the neurobiological mechanisms involved in antidepressant resistance and to develop valid models to test novel therapies that would be effective in patients that do not respond to traditional monoaminergic antidepressants.
Keywords: Animal model; Antidepressant; Behavior; Genetic; Pharmacology; Treatment resistant depression.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Faster, better, stronger: towards new antidepressant therapeutic strategies.Eur J Pharmacol. 2015 Apr 15;753:32-50. doi: 10.1016/j.ejphar.2014.07.046. Epub 2014 Aug 1. Eur J Pharmacol. 2015. PMID: 25092200 Review.
-
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatment.Pharmacol Biochem Behav. 2017 Oct;161:53-61. doi: 10.1016/j.pbb.2017.09.003. Epub 2017 Sep 11. Pharmacol Biochem Behav. 2017. PMID: 28911960
-
Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: a role for hippocampal cell proliferation.Neuroscience. 2013 Jan 3;228:36-46. doi: 10.1016/j.neuroscience.2012.09.072. Epub 2012 Oct 13. Neuroscience. 2013. PMID: 23069753
-
Treatment-resistant depression: are animal models of depression fit for purpose?Psychopharmacology (Berl). 2015 Oct;232(19):3473-95. doi: 10.1007/s00213-015-4034-7. Epub 2015 Aug 21. Psychopharmacology (Berl). 2015. PMID: 26289353 Review.
-
Using adjunctive treatments when first-line antidepressants fail.J Clin Psychiatry. 2012 Jan;73(1):e01. doi: 10.4088/JCP.10126tx4c. J Clin Psychiatry. 2012. PMID: 22316580
Cited by
-
Instantaneous antidepressant effect of lateral habenula deep brain stimulation in rats studied with functional MRI.Elife. 2023 Jun 1;12:e84693. doi: 10.7554/eLife.84693. Elife. 2023. PMID: 37261976 Free PMC article.
-
Long-Lasting Nociplastic Pain Modulation by Repeated Administration of Sigma-1 Receptor Antagonist BD1063 in Fibromyalgia-like Mouse Models.Int J Mol Sci. 2022 Oct 8;23(19):11933. doi: 10.3390/ijms231911933. Int J Mol Sci. 2022. PMID: 36233233 Free PMC article.
-
Animal models of major depression: drawbacks and challenges.J Neural Transm (Vienna). 2019 Nov;126(11):1383-1408. doi: 10.1007/s00702-019-02084-y. Epub 2019 Oct 4. J Neural Transm (Vienna). 2019. PMID: 31584111 Free PMC article. Review.
-
Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.IBRO Neurosci Rep. 2022 Sep 5;13:284-298. doi: 10.1016/j.ibneur.2022.08.009. eCollection 2022 Dec. IBRO Neurosci Rep. 2022. PMID: 36204253 Free PMC article.
-
Involvement of Anti-Inflammatory and Stress Oxidative Markers in the Antidepressant-like Activity of Aloysia citriodora and Verbascoside on Mice with Bacterial Lipopolysaccharide- (LPS-) Induced Depression.Evid Based Complement Alternat Med. 2022 Sep 22;2022:1041656. doi: 10.1155/2022/1041656. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36185078 Free PMC article.
References
-
- Agostinho FR, Reus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Benedet J, Rochi N, Scaini G, Streck EL, Quevedo J. Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain. Neurosci Lett. 2011a;487:278–281. - PubMed
-
- Agostinho FR, Reus GZ, Stringari RB, Ribeiro KF, Pfaffenseller B, Stertz L, Panizzutti BS, Kapczinski F, Quevedo J. Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neurosci Lett. 2011b;497:99–103. - PubMed
-
- Agostinho FR, Scaini G, Ferreira GK, Jeremias IC, Reus GZ, Rezin GT, Castro AA, Zugno AI, Quevedo J, Streck EL. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull. 2009;80:337–340. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
